BioNTech Investor Day Presentation Deck

BNT152 + BNT153 Combining with mRNA vaccine Per cent survival 100- 75- 50- 25- 0 BNT152 boosts therapeutic anti-tumor activity of BNT153 in combination with an RNA vaccine in the CT26 model 20 40 60 80 Days after tumor inoculation 100 Kranz LM, et al. SITC Annual Meeting 2019; Poster presentation 620. gp70 vaccine gp70 vaccine + BNT153 **** gp70 vaccine + BNT152 ns gp70 vaccine + BNT 153 + BNT152 **** BNT152 + BNT153 preferentially expands vaccine-induced CD8+ T cells Fold increase of CD8+ T cells 100,000 10,000 1,000 100 10 CD8+ T cells 7 days after 2nd treatment 1 vac: irr BNT 153: + mlL7: + Non-E7-specific E7-specific J₁J E7 E7 + **** + E7 ++ NUM + RiboCytokines BIONTECH 146

View entire presentation